Impact of anti-CD38 therapy in multiple myeloma with high-risk cytogenetics: systematic review and meta-analysis

Leuk Lymphoma. 2020 Oct;61(10):2519-2522. doi: 10.1080/10428194.2020.1772475. Epub 2020 Jun 6.

Authors

Ghulam Rehman Mohyuddin¹, Monia Sigle², Viveksandeep Thoguluva Chandrasekar², Muhammad Aziz³, Al-Ola Abdallah⁴, Leyla Shune⁴, Brian McClune⁵

Affiliations

¹ University of Kansas Cancer Center, Kansas City, KS, USA.
² School of Medicine, University of Kansas, Kansas City, KS, USA.
³ Department of Internal Medicine, University of Toledo, Toledo, OH, USA.
⁴ Department of Hematological Malignancies and Cellular Therapeutics, University of Kansas, Kansas City, KS, USA.
⁵ Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA.

PMID: 32508189
DOI: 10.1080/10428194.2020.1772475

No abstract available

Publication types

Letter
Meta-Analysis
Systematic Review

MeSH terms

ADP-ribosyl Cyclase 1 / genetics
Antibodies, Monoclonal
Cell Count
Humans
Multiple Myeloma* / drug therapy
Multiple Myeloma* / genetics

Substances

Antibodies, Monoclonal
ADP-ribosyl Cyclase 1